Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 291
Filter
Add more filters

Publication year range
1.
Brain Behav Immun ; 73: 403-415, 2018 10.
Article in English | MEDLINE | ID: mdl-29860025

ABSTRACT

Neonatal period is characterized by an immature intestinal barrier. Scattered evidence suggests that early life stressful events induce long lasting alterations of intestinal homeostasis mimicking Irritable Bowel Syndrome (IBS). Those observations highlighting defect of intestinal barrier by early life stress questioned its potential role as a risk factor for gastrointestinal disorders such as colitis and infections. In this study, we aimed to analyze if maternal separation (MS) in mice mimicks IBS main features. We next addressed whether MS could trigger or exacerbate colitis in genetically predisposed mice and/or enhance susceptibility to gastrointestinal infections in wild type mice. MS induced main features of IBS in adult wild type male mice i.e. intestinal hyperpermeability, visceral hypersensitivity, microbiota dysbiosis, bile acid malabsorption and low grade inflammation in intestine associated with a defect of Paneth cells and the ILC3 population. This breach in mucosal barrier functions in adults was associated with a systemic IgG response against commensal E. coli and increased IFNγ secretion by splenocytes. However, in IL10-/- mice, MS did not trigger nor worsen colitis. Furthermore, wild type mice submitted to MS did not show increase susceptibility to gastrointestinal infections (S. Typhimurium, L. monocytogenes or T. gondii) compared to controls. Altogether, our results identify MS in mice as a good experimental model for IBS mimicking all the main features. In addition, early life stress, even though it has long lasting consequences on intestinal homeostasis, does not constitute a facilitating factor to colitis in predisposed individuals nor to gastrointestinal infections in wild type mice.


Subject(s)
Irritable Bowel Syndrome/metabolism , Stress, Psychological/metabolism , Animals , Colitis/etiology , Colitis/pathology , Disease Models, Animal , Dysbiosis , Escherichia coli/pathogenicity , Gastrointestinal Diseases/microbiology , Gastrointestinal Diseases/physiopathology , Gastrointestinal Microbiome/physiology , Genetic Predisposition to Disease/genetics , Inflammation , Intestinal Mucosa/microbiology , Intestinal Mucosa/physiology , Intestines/microbiology , Intestines/physiology , Irritable Bowel Syndrome/physiopathology , Male , Maternal Deprivation , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Microbiota/physiology , Stress, Psychological/physiopathology
2.
J Radiol Prot ; 38(2): 471-479, 2018 06.
Article in English | MEDLINE | ID: mdl-29424360

ABSTRACT

The transmission factors used to calculate radiation shielding around an industrial x-ray device are determined using the MCNP6 code. The transmission factors are given for high voltages ranging between 120 and 800 kV for lead and between 200 and 800 kV for concrete. In view of the high usage intensity of industrial devices, the transmission factors are evaluated up to 1.10-10. The parameters used in the classic equation of Archer et al are derived from the transmission data calculated here. This type of data exists in the literature, but only for voltages lower than 150 kV to meet the design demands for facilities used in the medical field. In addition, this study markedly supplements the existing data, in particular for industrial and research installations.


Subject(s)
Manufacturing and Industrial Facilities , Radiation Dosage , Radiation Protection , X-Rays , Mathematical Computing , Radiation Protection/statistics & numerical data
3.
Am J Transplant ; 15(1): 190-9, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25496195

ABSTRACT

Pneumocystis pneumonia (PCP) in solid organ transplant (SOT) recipients becomes rare in the immediate posttransplantation period thanks to generalized prophylaxis. We aimed to identify the predictive factors for PCP in the era of universal prophylaxis and to propose a strategy for preventing PCP beyond the first year after transplantation. In a retrospective case-control study, 33 SOT cases with PCP diagnosed between 2004 and 2010 were matched with two controls each to identify risk factors for PCP by uni- and multivariate analysis. All the patients benefited from 6 months of posttransplantation trimethoprim-sulfamethoxazole prophylaxis. Most PCP in SOT patients occurred during the second year posttransplantation (33%). By univariate analysis, age, nonuse of tacrolimus, total and CD4 lymphocyte counts, gamma-globulin concentration and cytomegalovirus (CMV) infection appeared to be PCP risk factors. In the final multivariate analysis, age (adjusted odds ratio [OR] 3.7, 95% confidence interval [CI]: 1.3-10.4), CMV infection (OR: 5.2, 95% CI: 1.8-14.7) and total lymphocyte count (OR: 3.9, 95% CI: 1.4-10.7) were found to be independently associated with PCP. The second year posttransplantation appeared to be the new period of highest risk of PCP. Age, CMV viremia and lymphocytes were the most pertinent predictive criteria to evaluate the risk of PCP in clinical practice.


Subject(s)
Antibiotic Prophylaxis , Antifungal Agents/therapeutic use , Graft Rejection/etiology , Organ Transplantation , Pneumonia, Pneumocystis/etiology , Transplant Recipients , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Case-Control Studies , Cytomegalovirus/pathogenicity , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/microbiology , Female , Follow-Up Studies , Graft Rejection/diagnosis , Graft Rejection/drug therapy , Graft Survival , Humans , Immunocompromised Host , Male , Middle Aged , Pneumocystis carinii , Pneumonia, Pneumocystis/diagnosis , Pneumonia, Pneumocystis/drug therapy , Postoperative Complications , Retrospective Studies , Risk Factors , Tissue Donors
4.
Breast Cancer Res Treat ; 141(1): 101-10, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23942848

ABSTRACT

Clinical trials have shown the efficacy of trastuzumab-based adjuvant therapy in HER2-positive breast cancers, but routine clinical use awaits evaluation of compliance, safety, and effectiveness. Adjuvant trastuzumab-based therapy in routine clinical use was evaluated in the retrospective study GHEA, recording 1,002 patients treated according to the HERA protocol between March 2005 and December 2009 in 42 Italian oncology departments; 874 (87.23 %) patients completed 1-year trastuzumab treatment. In 128 patients (12.77 %), trastuzumab was withdrawn due to cardiac or non-cardiac toxicity (28 and 29 patients, respectively), disease progression (5 patients) or the clinician's decision (66 patients). In addition, 156 patients experienced minor non-cardiac toxicities; 10 and 44 patients showed CHF and decreased LVEF, respectively, at the end of treatment. Compliance and safety of adjuvant trastuzumab-based therapy in Italian hospitals were high and close to those reported in the HERA trial. With a median follow-up of 32 months, 107 breast cancer relapses were recorded (overall frequency, 10.67 %), and lymph node involvement, estrogen receptor negativity, lymphoid infiltration, and vascular invasion were identified as independent prognostic factors for tumor recurrence, indicating that relapses were associated with advanced tumor stage. Analysis of site and frequency of distant metastases showed that bone metastases were significantly more frequent during or immediately after trastuzumab (<18 months from the start of treatment) compared to recurrences in bone after the end of treatment and wash-out of the drug (>18 months from the start of treatment) (35.89 vs. 14.28 %, p = 0.0240); no significant differences were observed in recurrences in the other recorded body sites, raising the possibility that the protection exerted by trastuzumab is lower in bone metastases.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Carcinoma/drug therapy , Chemotherapy, Adjuvant , Adult , Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor , Breast Neoplasms/chemistry , Breast Neoplasms/pathology , Carcinoma/chemistry , Carcinoma/secondary , Combined Modality Therapy , Disease-Free Survival , Female , Follow-Up Studies , Genes, erbB-2 , Heart Diseases/drug therapy , Humans , Italy , Medication Adherence , Middle Aged , Neoadjuvant Therapy , Neoplasm Invasiveness , Neoplasm Metastasis , Neoplasm Proteins/analysis , Neoplasm Staging , Prognosis , Receptor, ErbB-2/analysis , Retrospective Studies , Risk Factors , Trastuzumab
5.
J Gynecol Obstet Hum Reprod ; 51(2): 102284, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34906693

ABSTRACT

INTRODUCTION: The "en caul" technique, i.e. delivery with intact membranes, may reduce the risk of obstetric trauma in vaginal breech delivery of extreme preterm infants. We aimed at comparing perinatal mortality and morbidity among extremely preterm breech vaginal deliveries between infants delivered "en caul" and those with "ruptured membranes". MATERIAL AND METHODS: We performed a fourteen-year retrospective study in a tertiary university center. All vaginal deliveries of singleton breech live infants with an antenatal decision of active resuscitation between 24 weeks and 27+6 weeks were included. Perinatal outcomes were compared between the "en caul" group, with intact membranes at the onset of pushing efforts and the "ruptured membranes" group, with ruptured membranes at the onset of pushing efforts. The primary outcome was perinatal mortality defined by intrapartum or neonatal death. The secondary outcomes were fetal extraction difficulties, arterial pH and 5 min Apgar score. RESULTS: We included 52 infants in the "en caul" group and 71 in the "ruptured membranes" group. The perinatal mortality rate did not differ between the two groups (19.2% in the "en caul" group versus 28.2% in the "ruptured membranes" group, p = 0.25). The mean arterial pH at birth was higher in the « en caul ¼ group (7.32 ± 0.1 vs 7.24 ± 0.1, p = 0.001). There were no differences between the groups for fetal extraction difficulties, especially fetal head entrapment (9.6% versus 9.9%). CONCLUSION: Even though the "en caul" technique does not seem to decrease the perinatal mortality rate, it remains a simple technique, which could improve neonatal morbidity.


Subject(s)
Breech Presentation , Delivery, Obstetric/methods , Infant, Extremely Premature , Adult , Female , Humans , Infant, Newborn , Perinatal Death , Pregnancy , Pregnancy Outcome , Retrospective Studies
6.
J Med Primatol ; 39(5): 315-7, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20444002

ABSTRACT

BACKGROUND: A 9-year-old, male castrate, Rhesus macaque was euthanized following a prolonged history of chronic renal failure. RESULTS: Necropsy revealed a proliferative lesion within the right cardiac auricle composed of neoplastic epithelioid cells which infiltrated the myocardium and frequently exhibited intracytoplasmic luminae. Cells multifocally exhibited strong cytoplasmic immunoreactivity for Factor VIII-related protein (von Willebrand's factor). CONCLUSIONS: The histological characteristics of this tumor are consistent with a diagnosis of epithelioid hemangioendothelioma, an intermediate-grade vasoformative neoplasm which has to our knowledge not previously been reported in the heart of a non-human species.


Subject(s)
Heart Neoplasms/veterinary , Hemangioendothelioma, Epithelioid/veterinary , Macaca mulatta , Monkey Diseases/pathology , Animals , Heart Atria/pathology , Heart Neoplasms/pathology , Hemangioendothelioma, Epithelioid/pathology , Male
7.
Clin Microbiol Infect ; 26(1): 115-121, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31158521

ABSTRACT

OBJECTIVES: Malaria is one of most common tropical diseases encountered in travellers and migrants. It requires an urgent and reliable diagnosis considering its potential severity. In this study, performance of five diagnostic assays were evaluated in a nonendemic region and compared prospectively to quantitative PCR (qPCR). METHODS: A prospective study was conducted at Toulouse Hospital from August 2017 to January 2018 and included all patients with initial Plasmodium screening. Thin and thick blood smears (TnS, TkS), quantitative buffy coat (QBC), rapid diagnostic tests (RDTs) and commercial loop-mediated isothermal amplification (LAMP) were independently performed on each blood sample and compared to our qPCR reference standard. RESULTS: The study encompassed 331 patients, mainly returning from Africa. qPCR detected 73 Plasmodium-positive samples (including 58 falciparum). Individually, LAMP had a 97.3% (71/73) sensitivity, far ahead of TnS (84.9%, 62/73), TkS (86.3%, 63/73), QBC (86.3%, 63/73) and RDT (86.3%, 63/73). RDT demonstrated a high sensitivity for falciparum (98.3%, 57/58) but missed all ovale, malariae and knowlesi infections. Specificity was excellent for all techniques (99.6-100%). The most sensitive diagnosis strategies were TnS + RDT (95.9%, 70/73), TnS + LAMP (97.3%, 71/73) and TnS + RDT + LAMP (100%, 73/73), about 10% higher than strategies using exclusively microscopy, TkS + TnS (87.7%, 64/73) or QBC + TnS (87.7%, 64/73). TnS remains necessary for Plasmodium species identification and quantification. Adding sequentially TnS only on LAMP-positive samples did not decrease TnS + LAMP strategy sensitivity. CONCLUSIONS: In nonendemic countries, the currently recommended microscopy-based strategies seem unsatisfactory for malaria diagnosis considering RDT and LAMP performance, two rapid and sensitive assays that require limited training.


Subject(s)
Communicable Diseases, Imported/diagnosis , Malaria/diagnosis , Microscopy/standards , Molecular Diagnostic Techniques/standards , Nucleic Acid Amplification Techniques/standards , Africa , Communicable Diseases, Imported/parasitology , France , Humans , Malaria/parasitology , Microscopy/methods , Molecular Diagnostic Techniques/methods , Nucleic Acid Amplification Techniques/methods , Plasmodium , Prospective Studies , Real-Time Polymerase Chain Reaction/standards , Sensitivity and Specificity , Temperature
9.
Ann Oncol ; 20(11): 1771-85, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19608616

ABSTRACT

BACKGROUND: Treatment options for patients with metastatic breast cancer (MBC) include a rapidly expanding repertoire of medical, surgical and supportive care measures. DESIGN: To provide timely and evidence-based recommendations for the diagnostic workup and treatment of patients with MBC, an international expert panel reviewed and discussed the evidence available from clinical trials regarding diagnostic, therapeutic and supportive measures with emphasis on their impact on the quality of life and overall survival of patients with MBC. RESULTS: Evidence-based recommendations for the diagnostic workup, endocrine therapy, chemotherapy, use of targeted therapies and bisphosphonates, surgical treatment and supportive care measures in the management of patients with MBC were formulated. CONCLUSIONS: The present consensus manuscript updates evidence-based recommendations for state-of-the-art treatment of MBC depending on disease-associated and biological variables.


Subject(s)
Antineoplastic Agents/therapeutic use , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Clinical Trials as Topic , Evidence-Based Medicine , Female , Humans , Mastectomy , Meta-Analysis as Topic , Prognosis
10.
Ann Oncol ; 19(10): 1706-12, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18544559

ABSTRACT

BACKGROUND: The standardization of the HER2 score and recent changes in therapeutic modalities points to the need for a reevaluation of the role of HER2 in recently diagnosed breast carcinoma. PATIENTS AND METHODS: A multicenter, retrospective study of 1794 primary breast carcinomas diagnosed in Italy in 2000/2001 and scored in HER2 four categories according to immunohistochemistry was conducted. RESULTS: Ductal histotype, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. HER2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months, HER2 3+ status was associated with higher relapse rates in node-positive and node-negative subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, especially taxanes. CONCLUSIONS: The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HER2 2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features.


Subject(s)
Breast Neoplasms/enzymology , Breast Neoplasms/therapy , Receptor, ErbB-2/biosynthesis , Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/pathology , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Immunohistochemistry , Mastectomy , Middle Aged , Retrospective Studies
11.
Radiat Prot Dosimetry ; 125(1-4): 180-4, 2007.
Article in English | MEDLINE | ID: mdl-17675663

ABSTRACT

ICRP 60 has defined the personal dose equivalent Hp(10) as an estimator of the effective dose E. Personal dosimeters, worn on the trunk, allow the measurement of the quantity Hp(10). However, the characteristics of the instrumentation and the definition of Hp(10) itself can generate differences between the two quantities, depending on the energies and on the directional distribution of the incident radiation. The objective of this study is to evaluate the possibility of the measurement of the effective dose E using an instrumented anthropomorphic phantom at workplaces. In the first step of this study, calculations of the effective dose for standard configurations are made using the Monte Carlo code MCNPX. This paper presents the model of the numerical anthropomorphic phantom and the results for whole body irradiations by broad unidirectional or plane-parallel photon beams. The results agree with those calculated by Zankl et al., so confirming the good suitability of the code and the phantom used. Then, the dose distributions inside some organs are presented and the locations of future detectors for the instrumented phantom are discussed.


Subject(s)
Body Burden , Models, Biological , Occupational Exposure/analysis , Organ Specificity , Radiation Protection/methods , Risk Assessment/methods , Whole-Body Counting/methods , Algorithms , Computer Simulation , Humans , Internationality , Occupational Exposure/prevention & control , Phantoms, Imaging , Relative Biological Effectiveness , Reproducibility of Results , Sensitivity and Specificity
12.
Radiat Prot Dosimetry ; 176(4): 365-379, 2017 Nov 01.
Article in English | MEDLINE | ID: mdl-28338860

ABSTRACT

Values of the new protection quantity 'Local Skin Dose' LSD, introduced by the International Commission on Radiological Protection (ICRP) Publication 116, were calculated for 134 ß- or ß+ emitting radionuclides, using the Monte Carlo code MCNP6. Two types of source geometry are considered: a point source and disc-type surface contamination (the source is placed in contact with the skin). This new protection quantity is compared with the operational quantity H'(0.07,0°), leading us to conclude that, in accordance with the rules of the ICRP, the operational quantity over-estimates the protection quantity to a reasonable extent, except in very rare cases for very low average beta energies. Thus, with the new skin model described in ICRP 116, there are no longer any major differences between the operational quantities and protection quantities estimated with the skin model described in ICRP 74.


Subject(s)
Radiation Dosage , Skin/radiation effects , Algorithms , Beta Particles , Humans , International Agencies , Models, Anatomic , Monte Carlo Method , Radiation Protection
13.
Gynecol Obstet Fertil Senol ; 45(2): 70-76, 2017 Feb.
Article in French | MEDLINE | ID: mdl-28368798

ABSTRACT

OBJECTIVES: Identify the factors associated with caesarean delivery for unengaged fetal head beyond 3hours of passive second stage of labor, among primiparous patients. METHODS: A case-control study conducted in level III universitary center between October 2012 and September 2015. Only primiparous at term, with a singleton, cephalic fetus and a passive second stage of labor prolonged over 3hours before pushing were included. During the second stage of labor, patients who had caesarean for abnormal fetal heart rate were excluded. Risk factors of cesarean were analyzed with univariate analysis and after statistical adjustment using multivariate logistic regression. RESULTS: The mean passive second stage duration was significantly longer among patients who had a caesarean (3h37±21min vs 3h13±19min [P=0,0001]). After multivariate logistic regression, factors associated with a risk of caesarean were body mass index higher than 30kg/m2 (OR=25.9 [3.1-215.9]). fetal macrosomia suspected by 3rd trimester ultrasound (OR=4.4 [1.2-16.4]), induction by prostaglandins (OR=5.7 [2.1-15.5]), a stagnation of cervical dilatation during the 1st stage (OR=[1.3-6.8]), and fetal occiput posterior position beyond 3hours (OR=30.7 [3.3-280.9]). CONCLUSIONS: Risk of caesarean delivery for unengaged fetal head beyond 3hours of passive second stage of labor is associated with maternal, fetal and obstetrical factors. Those factors might be taken into account before accept or not a 3rd hour at full cervical dilation.


Subject(s)
Cesarean Section/adverse effects , Labor Stage, Second , Obstetric Labor Complications , Adult , Body Mass Index , Case-Control Studies , Female , Fetal Macrosomia/complications , Fetal Macrosomia/diagnostic imaging , Humans , Labor Stage, First , Labor, Induced/adverse effects , Logistic Models , Parity , Pregnancy , Risk Factors , Time Factors , Ultrasonography, Prenatal
15.
Arch Pediatr ; 24(12): 1287-1292, 2017 Dec.
Article in French | MEDLINE | ID: mdl-29169715

ABSTRACT

Decisions regarding whether to initiate or forgo intensive care for extremely premature infants are often based on gestational age alone. However, other factors also affect the prognosis for these patients and must be taken into account. After a short review of these factors, we present the thoughts and proposals of the Risks and Pregnancy department. The proposals are to limit emergency decisions, to better take into account other factors than gestational age and prenatal predicted fetal weight in assessing the prognosis, to introduce multidisciplinary consultation in the evaluation and proposals that will be discussed with the parents, and to separate prenatal steroid therapy from decision-making regarding whether or not to administer intensive care.


Subject(s)
Perinatal Care , Algorithms , Female , Humans , Infant, Extremely Premature , Infant, Newborn , Pregnancy , Risk Factors
16.
Endocr Relat Cancer ; 13(1): 221-32, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16601290

ABSTRACT

A splice variant of the human gene HER2, lacking exon-16 (DeltaHER2) which encodes a small extracellular region, has been described. This altered receptor forms disulfide bond-stabilized homodimers. We report here that the DeltaHER2 splice variant represents about 9% of the HER2 mRNA obtained from most of the 46 breast carcinoma samples with HER2 expression levels ranging from 3+ to 0 by HercepTest. Analysis of human cells transfected with DeltaHER2 or wild-type (WT) cDNA revealed no growth of WT cells in nude mice, whereas clones expressing 10-fold less DeltaHER2 were tumorigenic. Unlike WT transfectants, DeltaHER2-expressing cells showed low sensitivity to two new therapeutic drugs targeting receptors of the HER family (ZD1839 and Trastuzumab), whereas an inhibitor of the HER2 tyrosine kinase domain (Emodin) blocked activation of both DeltaHER2 and WT transfectants. Taken together, our findings indicate that the DeltaHER2 transcript encodes the transforming form of the oncoprotein. It is plausible that malignant transformation arises when a critical threshold of DeltaHER2 is reached in HER2-overexpressing tumors. Specific inhibitors of HER2 catalytic activity represent a promising approach to therapy of HER2-overexpressing tumors.


Subject(s)
Breast Neoplasms/genetics , Exons/genetics , RNA Splicing , Receptor, ErbB-2/genetics , 3T3 Cells , Animals , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/therapeutic use , Apoptosis , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Cell Proliferation , Cells, Cultured , Drug Tolerance , Emodin/pharmacology , Enzyme Inhibitors/pharmacology , ErbB Receptors/antagonists & inhibitors , Flow Cytometry , Gefitinib , Gene Expression Regulation, Neoplastic , Humans , Kidney/drug effects , Kidney/metabolism , Mice , Mice, Inbred BALB C , Mice, Nude , Polymerase Chain Reaction , Quinazolines/therapeutic use , Receptor, ErbB-2/antagonists & inhibitors , Receptor, ErbB-2/metabolism , Trastuzumab
17.
J Natl Cancer Inst ; 54(2): 479-81, 1975 Feb.
Article in English | MEDLINE | ID: mdl-1172784

ABSTRACT

An antiserum obtained by the immunization of C57BL/HeDp mice with a pool of C3HF/Dp 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced fibrosarcomas exerted a specific cytotoxic activity in vitro on C57BL/HeDp chemically induced lymphosarcomas. Conversely, C57BL/HeDp spleen cells sensitized against C3Hf/Dp chemically induced lymphosarcomas or embryo cells were cytotoxic for plated cells of syngeneic DMBA-induced fibrosarcomas. Absorption studies with antiembryo and antilymphoma antisera showed that embryonic antigens were shared between lymphosarcomas and fibrosarcomas and that all serologically defined antigens present on lymphoma cells, including virus-related antigens, were also on fibrosarcoma cells.


Subject(s)
Antigens, Neoplasm/analysis , Embryo, Mammalian/immunology , Fibrosarcoma/immunology , Lymphoma, Non-Hodgkin/immunology , Animals , Antigens, Viral/analysis , Benz(a)Anthracenes , Cross Reactions , Cytotoxicity Tests, Immunologic , Fibrosarcoma/chemically induced , Immune Sera , Lymphoma, Non-Hodgkin/chemically induced , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Sarcoma, Experimental/chemically induced , Sarcoma, Experimental/immunology , Spleen/cytology
18.
J Natl Cancer Inst ; 75(5): 831-9, 1985 Nov.
Article in English | MEDLINE | ID: mdl-3863986

ABSTRACT

Ricin A chain was coupled to murine monoclonal antibodies MBr1 and MOv2 respectively raised against human breast and ovarian carcinomas. Inhibition of protein synthesis only occurred in those cultured human tumor cells bearing the appropriate target antigens, demonstrating that both components of the conjugate were unchanged in regards to specificity and toxicity. Conjugates were 125-200 times more efficient in inhibiting [3H]proline incorporation than the uncoupled ricin A chain. They were however unable to kill the entire population of the appropriate cells even after repeated treatment. Although the two monoclonal antibodies had similar binding kinetics, the conjugates differed in their cytotoxicity kinetics. The MBr1-ricin A chain conjugate had slow kinetics, and about 20 hours were needed to obtain a protein synthesis inhibition above 50% on the appropriate line (mammary carcinoma MCF-7). In contrast, the MOv2-ricin A chain conjugate showed very fast kinetics, reaching 50% inhibition after only 30 minutes of treatment on both appropriate cell lines SW626 and HT-29 from ovarian and colon carcinomas, respectively. Growth conditions of cell lines, i.e., adherent cells versus suspended cells, and plating time were found to greatly influence the conjugates' killing efficiencies. These studies confirm the possibility of preparing ricin A chain-antibody conjugates, which retain specific cytotoxicity against tumor cells; but they also underline the need for further in vitro studies of various parameters before one considers a therapeutic use of such conjugates.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Neoplasms/therapy , Ricin/administration & dosage , Antibodies, Monoclonal/immunology , Breast Neoplasms/immunology , Cell Line , Female , Humans , Kinetics , Neoplasm Proteins/biosynthesis , Neoplasms/metabolism , Neoplasms/pathology , Ovarian Neoplasms/immunology
19.
J Natl Cancer Inst ; 73(2): 363-9, 1984 Aug.
Article in English | MEDLINE | ID: mdl-6379256

ABSTRACT

Fusion of spleen cells from a mouse immunized with a surgical specimen of a human renal carcinoma with murine P3 myeloma cells resulted in the establishment of a hybridoma cell line that secreted a monoclonal antibody (MKi-1), of IgG1 subclass, which preferentially reacted on kidney crude membrane (CM) preparations. This monoclonal antibody was tested by solid-phase radioimmunometric assay and immunofluorescence (IF) on a panel of tumor cell lines and on CM preparations and cell suspensions from surgical specimens of normal and neoplastic tissues. In addition, cryosections of normal and cancer tissues of various histologic types were tested by IF. The expression of the MKi-1 antigen was limited to normal kidney epithelium, renal cancers, some areas in the pancreas, the apical region of some breast ducts, and a proportion (5-50%) of activated lymphocytes. Electron microscopic study by the immunoperoxidase technique on fixed sections from normal kidney showed that MKi-1 stained the brush border of almost all proximal tubules. The molecule recognized by MKi-1 was a single polypeptide chain with a molecular weight of 140,000.


Subject(s)
Antigens, Neoplasm/analysis , Urinary Bladder Neoplasms/immunology , Animals , Antibodies, Monoclonal , Cell Line , Humans , Immunoenzyme Techniques , Mice , Mice, Inbred BALB C , Neoplasms/immunology , Radioimmunoassay
20.
J Natl Cancer Inst ; 85(5): 398-402, 1993 Mar 03.
Article in English | MEDLINE | ID: mdl-8433393

ABSTRACT

BACKGROUND: The 67-kd laminin receptor is a cell-surface protein that binds laminin with high affinity. In vitro studies suggest that this protein is involved in the progression of human tumors to invasive cancers (metastasis), but there have been few in vivo studies. Identification of such proteins would allow development of therapies aimed at interfering with their mechanisms of action. PURPOSE: This large retrospective study was designed to investigate the association of expression of this laminin receptor molecule with established prognostic factors and overall survival in breast carcinoma patients. METHODS: We immunohistochemically stained archival paraffin-embedded sections of 1160 primary breast carcinomas, using an immunoperoxidase technique and the MLuC5 monoclonal antibody, which is specific for the 67-kd laminin receptor. Specimens were obtained from consecutive surgeries performed from January 1968 through December 1971. Patients with negative lymph nodes or involved regional nodes had been treated with surgery alone; those with positive axillary nodes had received surgery and radiotherapy. No chemotherapy had been administered until disease recurrence. The statistical analysis was carried out using the logrank method for the survival curves and the actuarial life table to calculate survival rates according to the different prognostic variables. RESULTS: We found statistically significant associations between laminin receptor expression and young age (P < .001), premenopausal status (P = .001), positive axillary lymph nodes (P = .01), peritumoral lymphatic invasion (P = .02), and the diameter of the tumor (P = .05). Moreover, the association of expression of the receptor protein with poor prognosis, as indicated by survival curves, was statistically significant (P < .01). For patients with receptor-negative tumors, the survival rate was 50% at 20 years; for those with receptor-positive tumors, the survival rate was 50% at 13 years. Multivariate analysis showed the laminin receptor to be an independent prognostic factor (P = .005), indicating its predictive value in relation to overall survival. CONCLUSIONS: Our data suggest that the 67-kd laminin receptor is associated with the metastatic process. IMPLICATIONS: These preliminary findings also suggest that hormones may have a regulatory role in the in vivo expression of the 67-kd laminin receptor, which supports the hypothesis that hormone therapy might inhibit expression of the receptor. Studies of expression of this receptor in tumors of patients with extremely different sex hormone levels (e.g., men and pregnant women) are in progress.


Subject(s)
Breast Neoplasms/chemistry , Receptors, Laminin/analysis , Antibodies, Monoclonal , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Female , Humans , Lymphatic Metastasis , Menopause , Middle Aged , Prognosis , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL